Summary
This study evaluated the quality of Indonesia's 2011 type 2 diabetes guideline, which was adapted from four international guidelines (IDF, AACE, ADA, and ADA/EASD). Using the AGREE II instrument, reviewers found the Indonesian guideline satisfied only 55% of quality items compared to 59–74% for its parent guidelines, with particular weakness in rigour of development and applicability. The analysis identified substantive differences in four key recommendations, highlighting gaps in transparent evidence-based adaptation and contextualisation processes.
UK applicability
Whilst this study is geographically specific to Indonesia's health system, it raises important methodological considerations applicable to UK guideline development: the importance of transparent derivation when adapting international guidelines, and the potential quality loss when guidelines are adapted without rigorous re-appraisal of underlying evidence. UK guideline bodies (such as NICE) may find value in the AGREE II assessment methodology demonstrated here.
Key measures
AGREE II instrument scores across domains (scope and purpose, stakeholder involvement, rigour of development, clarity of presentation, applicability, editorial independence); comparison of six specific clinical recommendations
Outcomes reported
The study assessed the quality of Indonesia's type 2 diabetes guideline using the AGREE II instrument and compared six clinical recommendations against four parent international guidelines. Quality scores and differences in recommendations between the Indonesian guideline and its parent sources were reported.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.